Most Read Articles
Roshini Claire Anthony, Yesterday

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.

Product Highlight - Erleada

26 Jun 2020
For your patients with high risk# nmCRPC
Prescribing Erleada may help them delay metastasis and/or live longer1

Erleada is a potent androgen receptor (AR) inhibitor indicated for the treatment of patients with high risk non-metastasis castration-resistant prostate cancer (nmCRPC)

In the SPARTAN Study1:
  • Erleada +ADT improved median Metastasis Free Survival after (MFS) for more than 2 years (24.3 months) compared with placebo + ADT (40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)1
  • Erleada + ADT when compared to ADT alone showed: 25% risk reduction in death and 51% risk reduction of PFS21
  • Erleada + ADT demonstrated statistically significant improvement in time to symptomatic progression, time to metastasis, PFS, time to PSA progression and PSA decline.1
  • Erleada provides convenience with once daily oral dosing.2
  • Erleada +ADT was well tolerated and maintained HRQoL of nmCRPC patients.1

#PSA doubling period ≤10 months; PFS: Progression Free Survival; ADT: Androgen deprivation therapy; PSA: Prostate specific antigen; HRQoL: Health-related Quality of Life


References:
1. Smith MR, et al. N Engl J Med. 2018;378(15):1408–18.
2. ERLEADA (apalutamide) approved prescribing information MalaysiaE uSmPC v Jan 2019


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.